“Keros Therapeutics Stock Takes a Nosedive: The Emotional Impact and Reasons Behind the 81% Plunge in Just 3 Months”
KROS Stock Crashes 81% After Halting Dosing with Cibotercept What Happened In a shocking turn of events, KROS stock has plummeted 81% in just three months after the company announced the halting of dosing with cibotercept in a phase II lung disease study. This decision came after several patients experienced adverse pericardial effusion events, leading…